NCT06426485View on ClinicalTrials.gov

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

736

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

June 30, 2027

Conditions

Major Depressive Disorder

Interventions

DRUG

Toludesvenlafaxine Hydrochloride Sustained-release Tablets

orally once a day

DRUG

placebo

orally once a day

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT06426485 - To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets | Biotech Hunter | Biotech Hunter